FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4229372331> ?p ?o ?g. }

• W4229372331 endingPage "79" @default.
• W4229372331 startingPage "71" @default.
• W4229372331 abstract "Background: Development a granuloma model resembling latent tuberculosis in vitro is needed with a fast and efficient time to be used as an effective therapy. This study aimed to form efficient granulomas, increase cellular immunity and humoral immunity, and evaluate growth on media using recombinant protein antibody Ag38kDa, Rifampicin, and a combination of both. Peripheral Blood Mononuclear Cell (PBMC) in vitro is derived from a healthy individual separated from monocytes and lymphocytes. Materials and methods: Monocytes are matured into macrophages and then combined macrophages and lymphocytes to the Roswell Park Memorial Institute (RPMI) medium. Flow cytometry analysis was used to count the number of cells, and cytokine levels were measured using ELISA. The result from the treatment was planted on the Lowenstein-Jensen medium. Results: Granulomas-like aggregates was formed after one-day post-infection with Mycobacterium tuberculosis (M.tb). A significant increase in immune response occurred in the number of macrophages, Th1, and Tregs in the combination group compared to the Mtb infection group. The number of Th2 and Th17 cells in the combination group was compared with the control but not significantly. TNF-α cytokine levels increased in the combination group compared to Mtb infection, while in IL-4, we found between all groups, there was no significant difference. Bacterial colonies on culture in the Lowenstein-Jensen medium were only seen in positive controls. Conclusion: Our study concluded that administration of a combination between Ag38kDa recombinant antibody and rifampicin could inhibit granuloma formation and enhance immune response." @default.
• W4229372331 created "2022-05-10" @default.
• W4229372331 creator A5011470021 @default.
• W4229372331 creator A5048777772 @default.
• W4229372331 creator A5052597048 @default.
• W4229372331 creator A5055652282 @default.
• W4229372331 creator A5078959404 @default.
• W4229372331 creator A5086311076 @default.
• W4229372331 date "2022-05-06" @default.
• W4229372331 modified "2023-09-25" @default.
• W4229372331 title "IMMUNE RESPONSE ON THE ADMINISTRATION OF RECOMBINANT PROTEIN ANTIBODIES AG-38 KDA MYCOBACTERIUM TUBERCULOSIS AND RIFAMPICIN EX-VIVO." @default.
• W4229372331 cites W1602010694 @default.
• W4229372331 cites W1646851899 @default.
• W4229372331 cites W165836434 @default.
• W4229372331 cites W1961512648 @default.
• W4229372331 cites W1980108230 @default.
• W4229372331 cites W1985859986 @default.
• W4229372331 cites W2012200136 @default.
• W4229372331 cites W2024943377 @default.
• W4229372331 cites W2035256770 @default.
• W4229372331 cites W2037566957 @default.
• W4229372331 cites W2038942016 @default.
• W4229372331 cites W2039102288 @default.
• W4229372331 cites W2067776060 @default.
• W4229372331 cites W2082386765 @default.
• W4229372331 cites W2092448486 @default.
• W4229372331 cites W2100990607 @default.
• W4229372331 cites W2123093300 @default.
• W4229372331 cites W2154401560 @default.
• W4229372331 cites W2161850401 @default.
• W4229372331 cites W2164488965 @default.
• W4229372331 cites W2165134407 @default.
• W4229372331 cites W2169023042 @default.
• W4229372331 cites W2405245899 @default.
• W4229372331 cites W2512141013 @default.
• W4229372331 cites W2771546270 @default.
• W4229372331 cites W2926523510 @default.
• W4229372331 cites W2950875755 @default.
• W4229372331 cites W2981928220 @default.
• W4229372331 cites W911516641 @default.
• W4229372331 doi "https://doi.org/10.21010/ajid.v16i2.8" @default.
• W4229372331 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35582059" @default.
• W4229372331 hasPublicationYear "2022" @default.
• W4229372331 type Work @default.
• W4229372331 citedByCount "0" @default.
• W4229372331 crossrefType "journal-article" @default.
• W4229372331 hasAuthorship W4229372331A5011470021 @default.
• W4229372331 hasAuthorship W4229372331A5048777772 @default.
• W4229372331 hasAuthorship W4229372331A5052597048 @default.
• W4229372331 hasAuthorship W4229372331A5055652282 @default.
• W4229372331 hasAuthorship W4229372331A5078959404 @default.
• W4229372331 hasAuthorship W4229372331A5086311076 @default.
• W4229372331 hasBestOaLocation W42293723311 @default.
• W4229372331 hasConcept C137061746 @default.
• W4229372331 hasConcept C142724271 @default.
• W4229372331 hasConcept C150903083 @default.
• W4229372331 hasConcept C159654299 @default.
• W4229372331 hasConcept C202751555 @default.
• W4229372331 hasConcept C203014093 @default.
• W4229372331 hasConcept C207001950 @default.
• W4229372331 hasConcept C26291073 @default.
• W4229372331 hasConcept C2776548049 @default.
• W4229372331 hasConcept C2777975735 @default.
• W4229372331 hasConcept C2778607973 @default.
• W4229372331 hasConcept C2778690821 @default.
• W4229372331 hasConcept C2779341262 @default.
• W4229372331 hasConcept C2781069245 @default.
• W4229372331 hasConcept C3017875465 @default.
• W4229372331 hasConcept C55493867 @default.
• W4229372331 hasConcept C71924100 @default.
• W4229372331 hasConcept C86803240 @default.
• W4229372331 hasConcept C8891405 @default.
• W4229372331 hasConceptScore W4229372331C137061746 @default.
• W4229372331 hasConceptScore W4229372331C142724271 @default.
• W4229372331 hasConceptScore W4229372331C150903083 @default.
• W4229372331 hasConceptScore W4229372331C159654299 @default.
• W4229372331 hasConceptScore W4229372331C202751555 @default.
• W4229372331 hasConceptScore W4229372331C203014093 @default.
• W4229372331 hasConceptScore W4229372331C207001950 @default.
• W4229372331 hasConceptScore W4229372331C26291073 @default.
• W4229372331 hasConceptScore W4229372331C2776548049 @default.
• W4229372331 hasConceptScore W4229372331C2777975735 @default.
• W4229372331 hasConceptScore W4229372331C2778607973 @default.
• W4229372331 hasConceptScore W4229372331C2778690821 @default.
• W4229372331 hasConceptScore W4229372331C2779341262 @default.
• W4229372331 hasConceptScore W4229372331C2781069245 @default.
• W4229372331 hasConceptScore W4229372331C3017875465 @default.
• W4229372331 hasConceptScore W4229372331C55493867 @default.
• W4229372331 hasConceptScore W4229372331C71924100 @default.
• W4229372331 hasConceptScore W4229372331C86803240 @default.
• W4229372331 hasConceptScore W4229372331C8891405 @default.
• W4229372331 hasIssue "2" @default.
• W4229372331 hasLocation W42293723311 @default.
• W4229372331 hasLocation W42293723312 @default.
• W4229372331 hasLocation W42293723313 @default.
• W4229372331 hasOpenAccess W4229372331 @default.
• W4229372331 hasPrimaryLocation W42293723311 @default.
• W4229372331 hasRelatedWork W124612284 @default.

• next